Literature DB >> 25000454

Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors.

L Castagna1, R Crocchiolo1, S Furst1, J El-cheikh, B Esterni2, A Granata1, A Stoppa3, R Boubdallah3, D Coso3, N Vey4, A Charbonnier, C Lemarie5, C Faucher1, C Chabannon6, D Blaise7.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25000454     DOI： 10.1038/bmt.2014.138

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

2.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

Authors:  A Bacigalupo; T Lamparelli; P Bruzzi; S Guidi; P E Alessandrino; P di Bartolomeo; R Oneto; B Bruno; M Barbanti; N Sacchi; M T Van Lint; A Bosi
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

3.  Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation.

Authors:  Didier Blaise; Reza Tabrizi; Jean-Marie Boher; Anne-Gaëlle Le Corroller-Soriano; Jacques-Olivier Bay; Nathalie Fegueux; Jean-Michel Boiron; Sabine Fürst; Luca Castagna; Christian Chabannon; Agnes Boyer-Chammard; Noël Milpied; Hélène Labussière-Wallet; Catherine Faucher; Valerie-Jeanne Bardou; Mohamad Mohty; Mauricette Michallet
Journal:  Cancer       Date:  2012-08-14       Impact factor: 6.860

4.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Robert J Soiffer; Jennifer Lerademacher; Vincent Ho; Fangyu Kan; Andrew Artz; Richard E Champlin; Steven Devine; Luis Isola; Hillard M Lazarus; David I Marks; David L Porter; Edmund K Waller; Mary M Horowitz; Mary Eapen
Journal:  Blood       Date:  2011-04-04       Impact factor: 22.113

5.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

6.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.

Authors:  Mohamad Mohty; Jacques-Olivier Bay; Catherine Faucher; Bachra Choufi; Karin Bilger; Olivier Tournilhac; Norbert Vey; Anne-Marie Stoppa; Diane Coso; Christian Chabannon; Patrice Viens; Dominique Maraninchi; Didier Blaise
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

7.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Authors:  Jürgen Finke; Wolfgang A Bethge; Claudia Schmoor; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Gérard Socié
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

8.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

9.  Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

Authors:  Mehdi Hamadani; William Blum; Gary Phillips; Patrick Elder; Leslie Andritsos; Craig Hofmeister; Lynn O'Donnell; Rebecca Klisovic; Sam Penza; Ramiro Garzon; David Krugh; Thomas Lin; Thomas Bechtel; Don M Benson; John C Byrd; Guido Marcucci; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

10.  Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.

Authors:  C Cable; M P Buzzeo; J D Schold; S Khan; H Leather; J Moreb; K Jamieson; J Scornik; R J Amdur; J R Wingard; V Reddy
Journal:  Bone Marrow Transplant       Date:  2009-06-22       Impact factor: 5.483
  10 in total
  1 in total

1.  The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.

Authors:  R Crocchiolo; L Castagna; S Furst; R Devillier; B Sarina; S Bramanti; J El-Cheikh; A Granata; S Harbi; L Morabito; C Faucher; A Rimondo; D Girardi; B Mohty; B Calmels; C Carlo-Stella; C Chabannon; R Bouabdallah; A Santoro; N Vey; P J Weiller; D Blaise
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.